Psilocybe Poisoning: Pathophysiology, Classification and Treatment. A Clinical Case Review

Summary

Psilocybe cubensis mushrooms, the main source of psilocybin in the Americas, have a long history of use in Mesoamerican rituals for inducing altered states of consciousness. Psilocybin is metabolized to psilocin, which acts on serotonin receptors and can alleviate depressive symptoms with fewer side effects than traditional treatments. Growing interest in psilocybin's therapeutic potential is leading to a reevaluation of its legal status as research continues to explore its benefits for mental health, particularly in major depressive disorder.

Study at a glance

Abstract

The Psilocybe cubensis mushroom is recognized as the primary source of psilocybin in the Americas, occurring naturally across various regions. This fungus has a long history of use in Mesoamerican rituals due to its capacity to induce altered states of consciousness. The defining characteristic of Psilocybe mushrooms is their psilocybin content. Following ingestion, psilocybin is metabolized into psilocin, which acts as a potent serotonergic agonist by interacting with serotonin receptors. The resulting physiological and psychoactive effects are linked to the activity at 5-HT receptors within the central nervous system, along with the release of glutamate. Throughout history, diverse Mesoamerican cultures incorporated hallucinogenic mushroom consumption into their ritual ceremonies. The Aztecs, for example, revered them as Teonanácatl, or " flesh of the gods," valuing their ability to shift the perception of reality. Interest in psilocybin has seen a resurgence in the scientific community, spanning from the ethnobotanical studies of R. Gordon Wasson in the 1950s to contemporary research into its therapeutic applications for depression. Studies have indicated that psilocybin can sustainably alleviate depressive symptoms, often with fewer side effects compared to conventional pharmacological treatments. The combination of the ancient ceremonial and religious use of Psilocybe mushrooms with their demonstrable therapeutic potential is prompting a reevaluation of their legal status as a Schedule I drug. Ongoing research is actively exploring the impact of psilocybin on various psychiatric disorders, yielding promising results, particularly in the treatment of major depressive disorder. As the evidence supporting its therapeutic benefits continues to accumulate, it suggests a future where these psychedelic compounds could play a vital role in global mental health.

Tags